Glucose Metabolism Disorders  >>  Symlin (pramlintide)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Symlin (pramlintide) / AstraZeneca
NCT00240253: A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Completed
4
200
US
pramlintide acetate
AstraZeneca
Type 2 Diabetes Mellitus
06/06
06/06
NCT00467649: A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Completed
4
112
US
pramlintide acetate (Symlin), Symlin, rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
AstraZeneca
Type 2 Diabetes Mellitus
04/08
04/08
NCT00442767: Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

Completed
4
8
US
Insulin, aspart or lispro, Pramlintide + Insulin, Pramlintide Acetate
Montefiore Medical Center, Amylin Pharmaceuticals, LLC.
Type 1 Diabetes Mellitus
02/09
02/09

Download Options